LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway
- PMID: 11592063
- DOI: 10.1002/1521-4141(2001010)31:10<2885::aid-immu2885>3.0.co;2-2
LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway
Abstract
The threshold, extent and termination of TCR activation is controlled in part by inhibitory co-receptors expressed on activated T cells. The lymphocyte activation gene product (LAG-3), a ligand for MHC class II molecules co-caps with the CD3/TCR complex and inhibits cell proliferation and cytokine secretion in response to CD3 signaling. We first investigated whether LAG-3 is localized in activated T cells in detergent-resistant membrane rafts enriched in glycosphingolipids and cholesterol. We showed that both LAG-3 and MHC class II are present in the cell fraction of glycosphingolipid-rich complexes (GSL complexes) before the assembly of the immunological synapse by CD3/TCR complex cross-linking. Using the LAG-3 intracytoplasmic region as bait in the yeast two-hybrid cloning system, we next identified a novel protein termed LAP for LAG-3-associated protein. LAP is encoded by a 1.8-kb RNA message in lymphocytes and encodes a 45-kDa protein that is expressed in most tissues. We showed that LAP binds specifically in vitro and in vivo to the Glu-Pro (EP) repeated motif present in the LAG-3 intracytoplasmic region. LAP also binds to the EP motif of another functionally important receptor, the PDGFR. Thus, LAP is a candidate molecule for a new type of signal transduction and/or coupling of clustered rafts to the microtubule networks that could explain how negative signaling of co-receptors may occur through molecules devoid of any immunoreceptor tyrosine-based inhibitory motif consensus sequence.
Similar articles
-
The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes.Int Immunol. 1999 Nov;11(11):1745-52. doi: 10.1093/intimm/11.11.1745. Int Immunol. 1999. PMID: 10545478
-
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling.J Immunol. 1998 Oct 15;161(8):4058-65. J Immunol. 1998. PMID: 9780176
-
T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding.Eur J Immunol. 1996 May;26(5):1180-6. doi: 10.1002/eji.1830260533. Eur J Immunol. 1996. PMID: 8647185
-
Internalization and intracellular fate of TCR-CD3 complexes.Crit Rev Immunol. 2000;20(4):325-46. Crit Rev Immunol. 2000. PMID: 11100805 Review.
-
Selected signalling proteins recruited to the T-cell receptor-CD3 complex.Immunology. 2018 Jan;153(1):42-50. doi: 10.1111/imm.12809. Epub 2017 Sep 5. Immunology. 2018. PMID: 28771705 Free PMC article. Review.
Cited by
-
Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab.Oncoimmunology. 2015 Nov 25;5(4):e1100788. doi: 10.1080/2162402X.2015.1100788. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141381 Free PMC article.
-
Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets.Front Immunol. 2022 May 20;13:864202. doi: 10.3389/fimmu.2022.864202. eCollection 2022. Front Immunol. 2022. PMID: 35669786 Free PMC article. Review.
-
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.J Hematol Oncol. 2023 Sep 5;16(1):101. doi: 10.1186/s13045-023-01499-1. J Hematol Oncol. 2023. PMID: 37670328 Free PMC article. Review.
-
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.Mol Oncol. 2015 Dec;9(10):1936-65. doi: 10.1016/j.molonc.2015.10.008. Epub 2015 Oct 26. Mol Oncol. 2015. PMID: 26578451 Free PMC article. Review.
-
Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints.Cancers (Basel). 2023 May 16;15(10):2774. doi: 10.3390/cancers15102774. Cancers (Basel). 2023. PMID: 37345111 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous